A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Public ClinicalTrials.gov record NCT05920356. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Study identification
- NCT ID
- NCT05920356
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 750 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2023
- Primary completion
- Jun 29, 2027
- Completion
- Jun 28, 2032
- Last update posted
- Aug 26, 2026
2023 – 2032
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sansum Clinic | Santa Barbara | California | 93105 | Recruiting |
| Medical Oncology Hematology Consultants Helen F Graham Cancer Center | Newark | Delaware | 19713 | Recruiting |
| Florida Clinical Trials Group Plantation | Plantation | Florida | 33322 | Recruiting |
| Florida Clinical Trials Group Tamarac | Tamarac | Florida | 33321 | Recruiting |
| University of Illinois Chicago | Chicago | Illinois | 60612 | Recruiting |
| Illinois Cancer Specialists | Niles | Illinois | 60714 | Recruiting |
| Norton Cancer Institute - Brownsboro | Louisville | Kentucky | 40241 | Completed |
| Reliant Medical Group Inc | Worcester | Massachusetts | 01606 | Recruiting |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87131 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Terminated |
| Messino Cancer Centers Asheville | Asheville | North Carolina | 28806 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710 | Recruiting |
| FirstHealth Cancer Center | Pinehurst | North Carolina | 28374 | Recruiting |
| Dayton Physician's Network | Dayton | Ohio | 45415 | Recruiting |
| Alliance Cancer Specialists - Media | Media | Pennsylvania | 19063 | Recruiting |
| University of Pittsburgh Medical Center Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Terminated |
| University of Tennessee Medical Center Knoxville | Knoxville | Tennessee | 37920 | Terminated |
| Regional One Health | Memphis | Tennessee | 38103 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| United States Oncology Regulatory Affairs Corporate Office | Nashville | Tennessee | 37203 | Recruiting |
| Oncology Consultants PA | Houston | Texas | 77030 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| US Oncology Research Investigational Products Center | Irving | Texas | 75063 | Recruiting |
| Vista Oncology Inc PS | Olympia | Washington | 98506 | Recruiting |
| Mercyhealth | Janesville | Wisconsin | 53548 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 389 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05920356, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05920356 live on ClinicalTrials.gov.